Foeng, J.Comerford, I.McColl, S.R.2022-05-182022-05-182022Cell Reports Medicine, 2022; 3(3):100543-1-100543-152666-37912666-3791https://hdl.handle.net/2440/135149CAR-T cell therapy has been heralded as a breakthrough in the field of immunotherapy, but to date, this suc- cess has been limited to hematological malignancies. By harnessing the chemokine system and taking into consideration the chemokine expression profile in the tumor microenvironment, CAR-T cells may be homed into tumors to facilitate direct tumor cell cytolysis and overcome a major hurdle in generating effective CAR-T cell responses to solid cancers.en© 2022 The Author(s). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).T-LymphocytesHumansNeoplasmsReceptors, Antigen, T-CellChemokinesImmunotherapy, AdoptiveTumor MicroenvironmentT-LymphocytesHumansNeoplasmsReceptors, Antigen, T-CellChemokinesImmunotherapy, AdoptiveTumor MicroenvironmentJournal article10.1016/j.xcrm.2022.1005432022-05-17606769McColl, S.R. [0000-0003-0949-4660]